» Articles » PMID: 38831470

IFI16 Promotes the Progression of Clear Cell Renal Cell Carcinoma Through the IL6/PI3K/AKT Axis

Overview
Journal J Transl Med
Publisher Biomed Central
Date 2024 Jun 3
PMID 38831470
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Clear cell renal cell carcinoma (ccRCC) is a common disease in the urinary system, with a high incidence and poor prognosis in advanced stages. Although γ-interferon-inducible protein 16 (IFI16) has been reported to play a role in various tumors, its involvement in ccRCC remains poorly documented, and the molecular mechanisms are not yet clear.

Methods: We conducted bioinformatics analysis to study the expression of IFI16 in ccRCC using public databases. Additionally, we analyzed and validated clinical specimens that we collected. Subsequently, we explored the impact of IFI16 on ccRCC cell proliferation, migration, and invasion through in vitro and in vivo experiments. Furthermore, we predicted downstream molecules and pathways using transcriptome analysis and confirmed them through follow-up experimental validation.

Results: IFI16 was significantly upregulated in ccRCC tissue and correlated with poor patient prognosis. In vitro, IFI16 promoted ccRCC cell proliferation, migration, and invasion, while in vivo, it facilitated subcutaneous tumor growth and the formation of lung metastatic foci. Knocking down IFI16 suppressed its oncogenic function. At the molecular level, IFI16 promoted the transcription and translation of IL6, subsequently activating the PI3K/AKT signaling pathway and inducing epithelial-mesenchymal transition (EMT).

Conclusion: IFI16 induced EMT through the IL6/PI3K/AKT axis, promoting the progression of ccRCC.

Citing Articles

DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma.

Yang L, Feng Y, Liu X, Zhang Q, Liu Y, Zhang X Invest New Drugs. 2025; .

PMID: 39934438 DOI: 10.1007/s10637-024-01495-3.


Critical role of non-coding RNA-mediated ferroptosis in urologic malignancies.

Li W, Zheng L, Luo P, Chen T, Zou J, Chen Q Front Immunol. 2024; 15:1486229.

PMID: 39544949 PMC: 11560455. DOI: 10.3389/fimmu.2024.1486229.


Identification of PI3K-AKT Pathway-Related Genes and Construction of Prognostic Prediction Model for ccRCC.

Hu S, Zhang X, Xin H, Guo M, Xiao Y, Chang Z Cancer Rep (Hoboken). 2024; 7(9):e70010.

PMID: 39233640 PMC: 11375326. DOI: 10.1002/cnr2.70010.

References
1.
Takahashi M, Tsukamoto Y, Kai T, Tokunaga A, Nakada C, Hijiya N . Downregulation of WDR20 due to loss of 14q is involved in the malignant transformation of clear cell renal cell carcinoma. Cancer Sci. 2016; 107(4):417-23. PMC: 4832870. DOI: 10.1111/cas.12892. View

2.
Gillmore J, Lovat L, Persey M, Pepys M, Hawkins P . Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358(9275):24-9. DOI: 10.1016/S0140-6736(00)05252-1. View

3.
Yu B, Zheng X, Sun Z, Cao P, Zhang J, Wang W . Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma and Prediction of Patient Survival. Front Genet. 2021; 12:599952. PMC: 7917296. DOI: 10.3389/fgene.2021.599952. View

4.
Kaur S, Bansal Y, Kumar R, Bansal G . A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors. Bioorg Med Chem. 2020; 28(5):115327. DOI: 10.1016/j.bmc.2020.115327. View

5.
Miossec P, Kolls J . Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012; 11(10):763-76. DOI: 10.1038/nrd3794. View